Handelnine Global recalls Rheumacare capsules because product was found to contain lead
The notice says Rheumacare capsules in 30 count bottles were found to contain lead, and the product had manufacturing practice deviations; 4 bottles were sent to one customer in NY.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt. Ltd., Ahmedabad, India UPC 8 904218 700313
- Company
- Handelnine Global LLC
- Hazard
- CGMP Deviations: product found to contain lead.
- Units
- 4 bottles /30 capsules each
- Where sold
- Product was distributed to one customer in NY.
- FDA classification
- Class I · Ongoing
- Classified by FDA
- February 12, 2026
- Recall started
- December 22, 2025
- FDA enforcement report
- February 11, 2026
- Identifiers
- Codes: Lot: CAM040, Exp. 06/30/2029 Lot: CAL079-N, Exp. 09/30/2028
- FDA recall number: D-0332-2026
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt. Ltd., Ahmedabad, India UPC 8 904218 700313
- Reason for recall
- CGMP Deviations: product found to contain lead.
- Classification
- Class I (Ongoing)
- Distribution
- Product was distributed to one customer in NY.
- Quantity
- 4 bottles /30 capsules each
Related recalls
Acella recalls naproxen oral suspension over lead and lithium contamination
The recalled naproxen liquid, a prescription medicine sold in 16 fl oz (473 mL) bottles, contains lead and lithium above the allowed limits, and the notice covers 6,336 bottles sold nationwide.
Acella Pharmaceuticals, LLC · 6,336 bottles